Background -The benefit of adding theophylline to #2 agonists in acute asthmatic attacks has been debated frequently. Methods -In an open randomised study 25 patients with severe acute asthma who presented to the emergency department were treated with either a combined nebulised salbutamol (5 mg/dose) and aminophylline infusion (0-60-9 mg/kg/ hour), or nebulised salbutamol alone. Results -The responses to treatment as measured by peak expiratory flow (PEF) and the time taken to achieve maximum PEF were similar in both groups. Side effects were observed more commonly in patients receiving the combined treatment. Conclusions -Nebulised salbutamol is equally efficacious in acute asthma when given alone or in combination with aminophylline.
Theophylline has been used to treat bronchospasm for more than 50 years.' It has non-linear pharmacokinetics with a narrow therapeutic range.2 A small rise in the dose can be associated with a large increase in the serum concentration which may lead to dangerous adverse effects including death.3 Combined treatment with a nebulised adrenergic agent and parenteral aminophylline, either as a bolus or an infusion, is widely used for the treatment of acute severe asthma, although the benefit is not clear and the potential deleterious side effects are real. We have studied the efficiacy of, and cardiovascular responses to, combined aminophylline and nebulised salbutamol compared with nebulised salbutamol alone in patients with severe acute asthma.
Methods
Twenty five patients aged between 18 and 60 years who presented to the Accident and Emergency Department, General Hospital, Kuala Lumpur with a severe asthmatic attack were studied between June 1991 and January 1992 after their consent was obtained. They were randomised into two treatment groups: 11 in group A and 14 in group B. Ten of the 11 patients in group A and 13 of the 14 in group B were receiving oral theophylline as one of their antiasthma medications. Five of the 25 patients (two in group A and three in group B) had been given an intravenous bolus of aminophylline 16-36 hours before the admission for their deteriorating symptoms of asthma. Patients in group A were treated with nebulised salbutamol, 5 mg in 3 ml normal saline inhaled via a mouthpiece from a hand held jet nebuliser (Peri-Gerat 37.0002, Paul Ritzau, Starnberg, Germany) at the beginning of the study, then hourly for three hours, three hourly for the next nine hours, four hourly for 12 hours, and reducing to six hourly the following day if the patient's condition improved. They also received aminophylline infusion in dextrose 5% at a rate of 06-0 9 mg/kg/hour for 48 hours. Patients in group B received nebulised salbutamol in the same way as group A but without the aminophylline infusion. In addition, all patients received intravenous hydrocortisone 100 mg six hourly in the first 24 hours; this was changed on the following day to oral prednisolone 30 mg daily for two days, then 20 mg daily for two days, followed by 10 mg daily for the next two days. Oxygen 45% was given via a Hudson mask to all patients at least for the first 24 hours.
The severity of the asthma was assessed at enrolment by clinical examination, and measurement of arterial blood gas tensions and peak expiratory flow rate (PEF) any time of measurement. The mean (SD) time to achieve the maximum PEF values were 818 (315) hours v 68 6 (25 9) hours for groups A and B respectively. The difference is not significant. The cardiovascular response in terms of heart rate is shown in fig 2. All patients had sinus tachycardia, particularly for the first six hours, which fell with the improvement in lung function. The heart rate was significantly faster in group A than group B at 12 and 36 hours, and a similar trend was present throughout the treatment period. Systolic blood pressure changes were similar between the two groups (13 (9) mmHg for group A v 12 (13) mmHg for group B). Fourteen episodes of cardiac arrhythmias were noted in group A (four atrial ectopics, eight ventricular ectopics, one bigeminy, one short run of ventricular tachycardia) and 16 in group B (seven atrial ectopics, nine ventricular ectopic, one short run ventricular tachycardia). These were not significantly different. Patients in group A experienced significantly more symptoms of side effects (seven tremor, seven palpitation, nine insomnia, three nausea) than those in group B (one palpitation, four insomnia). Serum theophylline levels at 0, five, and 20 hours were 5-7 (2-4) mg/I, 10 2 (2-5) mg/I, 14 0 (1 6) mg/l for group A, and 9 7 (2-6) mg/I, 7 4 (2 1) mg/I, 3-1 (1 7) mg/l for 
Discussion
An intravenous bolus of aminophylline has been shown to be either equally or less efficacious than parenteral or nebulised ,B adrenergic agonists in the treatment of acute severe asthma.A5 Studies comparing the combination of aminophylline with a f3 adrenergic agent compared with a , adrenergic alone are, however, conflicting, either in favour of the combination therapy6 or showing no difference between the two regimens.7 Our results also fail to detect any difference in therapeutic response between combined aminophylline with nebulised salbutamol and nebulised salbutamol alone. Although our study was not blind and involved a relatively small number of subjects, the results would not be expected to differ with a larger group of patients as no trend in favour of either treatment was observed. The lack of benefit of adding aminophylline to nebulised ,B agonists was also noted in a meta-analysis looking at the role of aminophylline in acute asthma, although a trend was detected favouring its combination with injected ,B agonists. 8 The overall cardiovascular responses did not differ significantly between the combined treatment and salbutamol alone, except for the faster heart rate observed in the combined group. This is supported by symptoms of palpitation which were more common in this group. Tachycardia, which was seen in all patients at the beginning of treatment, improved with the improvement in lung function in both groups. The incidence of arrhythmia was similar in both groups but no patient had a sufficiently severe arrhythmia to cause haemodynamic disturbances. The incidence of arrhythmia was relatively small and tended to be transient, partly because the serum theophylline concentration was maintained within the therapeutic range in most patients. This is in keeping with the findings of others.9 The incidence and the severity of cardiac arrhythmias has been shown to increase when the aminophylline concentration exceeds the therapeutic range.'0 Although the incidence of cardiac arrhythmia was similar, the incidence of side effects in our study and others410 was substantially higher in those patients treated with a combination of aminophylline with a adrenergic agent.
We conclude that the addition of aminophylline infusion increases the toxicity, but not the efficacy, of nebulised salbutamol in the treatment of acute severe asthma. 
